Local time

22 02 2018

Lithuania

Bulgaria

Romania

Czech Republic

Slovakia

Poland

Hungary

Croatia

CEE

Hot pharma & economy news

Print -

World pharma news

  • RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) and Flatiron Health, Inc. announced that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018.
    Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
  • On average, 1 in 10 children who enroll in pediatric phase I cancer trials are improved after the trial, and 1 in 50 die from drug-related complications, according to a new systematic review and meta-analysis published this week in PLOS Medicine by Jonathan Kimmelman from McGill University, Canada, and colleagues.
    Study weighs risks and benefits of phase I trials in pediatric cancer
  • MerckMerck, a leading science and technology company, today announced ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel. For this purpose the strategic corporate venture capital arm of Merck has partnered with Arkin Holdings, Pontifax and WuXi AppTec to create the € 20 million pre-seed investment vehicle.
    Merck and three partners start ExploreBio, a € 20 million pre-seed investment initiative in Israel
  • Researchers have found that excess levels of calcium in brain cells may lead to the formation of toxic clusters that are the hallmark of Parkinson's disease. The international team, led by the University of Cambridge, found that calcium can mediate the interaction between small membranous structures inside nerve endings, which are important for neuronal signalling in the brain, and alpha-synuclein, the protein associated with Parkinson's disease.
    Calcium may play a role in the development of Parkinson's disease
  • NovartisNovartis and the Bill & Melinda Gates Foundation have formed an alliance to advance development of Novartis' drug candidate KDU731 for the treatment of cryptosporidiosis. Diarrheal diseases are one of the leading causes of childhood mortality globally, resulting in approximately 525,000 deaths each year and cryptosporidiosis is the second leading cause of infectious diarrhea in children under 2 years of age[1]-[2].
    Novartis forms alliance to develop medicines for treating infectious diarrheal disease

Pharmaceuticals News & Press Releases

McKinsey Quarterly

Pharma Marketing

  • Raises Price of Viagra<br /> <br /> Pfizer, the largest stand-alone pharmaceutical company in the US, raised the average wholesale price of 148 drugs by between 6 and 13.5 per cent, according to data, with a mean average increase of 8.8 per cent.
    Pfizer's "Dick" Move
  • Despite Hope in New Drugs<br /> <br /> According to the CDC, the average life expectancy at birth in the U.S. fell by 0.1 years, to 78.6, in 2016, following a similar drop in 2015. This is the first time in 50 years that life expectancy has fallen for two years running. In 25 other developed countries, life expectancy in 2015 averaged 81.8 years.
    Drop in U.S. Life Expectancy
  • Companies Leading the Way Implementing Disruptive Innovations<br /> <br /> This article features several examples of what the pharmaceutical industry is doing to implement disruptive digital innovations that help them manage clinical trials, improve their products, and support healthcare professionals and patients.
    The Pharma Digital Health Accelerator Club

Lithuania Economy

Latvia Economy

Estonia Economy

Czech Rep. Economy

Poland Economy

Slovakia Economy

Hungary Economy